Panel nixes Merck challenge to Sanofi's Nasacort ad claims; Wales MS patients win access to Bayer drug;

> A national panel has nixed a Merck ($MRK) challenge to advertising claims by Sanofi's ($SNY) Chattem over the company's newly launched Nasacort allergy nasal spray. Story

> Multiple sclerosis patients in Wales have won access to Bayer's Sativex. Report

> Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer. Release

> The FDA is seeking a new director for the Center for Drug Evaluation and Research's Office of Medical Policy, which oversees the Office of Prescription Drug Promotion. More

> A judge has side with Depomed in its patent litigation suit against Actavis ($ACT), whose generic of Depomed's Gralise will now be delayed until 2024. Release

> India's Organization of Pharmaceutical Producers of India is asking the Department of Pharmaceuticals to make its Uniform Code of Pharmaceutical Marketing Practices a statutory code. More

Suggested Articles

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.